The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) feasibility study: A randomized controlled trial

MA Roberts; HL Pilmore; FL Ierino; SV Badve; A Cass; AX Garg; NM Isbel; H Krum; EM Pascoe; V Perkovic; A Scaria; AM Tonkin; LA Vergara; CM Hawley; A Levin; D Hare; A Martin; DC Wheeler; G Fulcher; H Brown; D Colquhoun; D Korczyk; A Mather; A Wong; P Bisscheroux; A Gillies; L Garvey; KS Tan; E Lennan; M Pitkin; K Ahearn; RP Carroll; E Scott; B Cooper; J Pearse; P Snelling; J Burman; S Hand; E Pedagogos; C Karschimkus; A Pilmore; R Walker; G Ellis; MR Marshall; C Paul; D Johnson; J Helyar; A Morrish; PA Paul-Brent; D Reidlinger; L Zhang

Journal article

The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) feasibility study: A randomized controlled trial

MA Roberts, HL Pilmore, FL Ierino, SV Badve, A Cass, AX Garg, NM Isbel, H Krum, EM Pascoe, V Perkovic, A Scaria, AM Tonkin, LA Vergara, CM Hawley, A Levin, D Hare, A Martin, DC Wheeler, G Fulcher, H Brown Show all

American Journal of Kidney Diseases | W B SAUNDERS CO-ELSEVIER INC | Published : 2016

DOI: 10.1053/j.ajkd.2015.10.029

Abstract

Background β-Blocking agents reduce cardiovascular mortality in patients with heart disease, but their potential benefit in dialysis patients is unclear. We aimed to determine the feasibility of a randomized controlled trial (RCT). Study Design Pilot RCT. Setting & Participants Patients who received dialysis for 3 or more months and were 50 years or older (or ≥18 years with diabetes or cardiovascular disease) were recruited from 11 sites in Australia and New Zealand. We aimed to recruit 150 participants. Intervention After a 6-week run-in with the β-blocker carvedilol, we randomly assigned participants to treatment with carvedilol or placebo for 12 months. Outcomes & Measurements The prespec..

View full abstract